🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial

  2. A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

    Pfizer Australia Pty Ltd

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    phase 1 other active

    1 trial

  3. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  4. A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors

    Revolution Medicines

    Participants with Advanced KRASG12C-Mutated Solid Tumors

    phase 1 other active

    1 trial

  5. A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations, Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

    phase 1 other active

    1 trial

  6. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  7. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  8. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  9. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  10. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  11. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  12. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  13. A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors

    AstraZeneca AB

    Advanced solid tumour

    phase 1 other active

    1 trial

  14. A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  15. AB308

    Arcus Biosciences

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  16. AB598

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  17. AB680

    Arcus Biosciences

    Advanced Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  18. AB801

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  19. ACR-2316

    Acrivon Therapeutics

    Specific Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  20. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials

  21. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.

    Pfizer Australia Pty Ltd

    metastatic/advanced breast cancer

    phase 1 other active

    1 trial

  23. ALLO-316

    Allogene Therapeutics

    Advanced/Metastatic Clear Cell Renal Cell Carcinoma

    phase 1 gene therapy active

    1 trial

  24. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources